Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck

Bae, Woo Kyun; Hwang, Jun Eul; Shim, Hyun Jeong; Cho, Sang‐Hee; Lee, Ki Hyeong; Han, Hye Sung; Song, Eun-Kee; Yun, Hwan Jung; Cho, In Sung; Lee, Joon Kyoo; Lim, Sang-Chul; Chung, Woong‐Ki; Chung, Ik‐Joo

doi:10.1186/1471-2407-13-102

Cited by 12 publications

(12 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 5-fluorouracil (5-FU) has been replaced by capecitabine, 29 ifosfamide, 24,26 cetuximab, 23 and gemcitabine. 34 Other authors have replaced docetaxel with paclitaxel 24,25,27,28 or split the docetaxel dose (biweekly docetaxel) 35 to reduce hematological toxicity, whereas others omit the third agent. 36 By contrast, the TPF regimen affects the administration of definitive locoregional treatment in the majority of patients with locally advanced HNSCC.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…This injection schedule mirrors the clinical setting where, for example, patients receive weekly chemotherapy. 31–33 Also, longitudinal imaging protocols to assess treatment success may be carried out at similar time frames. We sought to determine PVX-specific serum IgM and IgG antibody levels resulting from the repeat administrations of PVX.…”

Section: Resultsmentioning

confidence: 99%

Multiple Administrations of Viral Nanoparticles Alter in Vivo Behavior—Insights from Intravital Microscopy

Shukla¹,

Dorand²,

Myers³

et al. 2016

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Multiple administrations of nanoparticle-based formulations are often a clinical requirement for drug delivery and diagnostic imaging applications. Steady pharmacokinetics of nanoparticles is desirable to achieve efficient therapeutic or diagnostic outcomes over such repeat administrations. While clearance through mononuclear phagocytic system is a key determinant of nanoparticle persistence in vivo, multiple administrations could potentially result in altered pharmacokinetics by evoking innate or adaptive immune responses. Plant viral nanoparticles (VNPs) represent an emerging class of programmable nanoparticle platform technologies that offer a highly organized proteinaceous architecture and multivalency for delivery of large payloads of drugs and molecular contrast agents. These very structural features also render them susceptible to immune recognition and subsequent accelerated systemic clearance that could potentially affect overall efficiency. While the biodistribution and pharmacokinetics of VNPs have been reported, the biological response following repeat administrations remains an understudied area of investigation. Here, we demonstrate that weekly administration of filamentous plant viruses results in the generation of increasing levels of circulating, carrier-specific IgM and IgG antibodies. Furthermore, PVX specific immunoglobulins from the serum of immunized animals quickly form aggregates when incubated with PVX in vitro. Such aggregates of VNP-immune complexes are also observed in the mouse vasculature in vivo following repeat injections when imaged in real time using intravital two-photon laser scanning microscopy (2P-LSM). The size of aggregates diminishes at later time points, coinciding with antibody class switching from IgM to IgG. Together, our results highlight the need for careful in vivo assessment of (viral) nanoparticle-based platform technologies, especially in studying their performance after repeat administration. We also demonstrate the utility of intravital microscopy to aid in this evaluation.

show abstract

“…The value contributed by the addition of 5‐FU into an induction chemotherapy regimen is controversial. Although most induction trials have used TPF triple therapy, a small set of articles have been published using TP‐based induction chemotherapy . These articles show similar efficacy and substantially lower toxicity profiles, therefore improving the viability and adherence to induction protocols.…”

Section: Discussionmentioning

confidence: 99%

Presurgical induction chemotherapy for squamous cell carcinoma of the tonsil

et al. 2019

View full text Add to dashboard Cite

Objectives/Hypothesis: The indications for and efficacy of induction chemotherapy in the management of squamous cell carcinoma of the head and neck is controversial. With the advent of human papillomavirus (HPV)-related cancers, survival has improved significantly. Here we present a group of patients with tonsil cancer treated with induction chemotherapy followed by surgery.Study Design: Retrospective cohort study. Methods: Thirty-eight patients with tonsil cancer were treated with induction chemotherapy, consisting of cisplatin and docetaxel, followed by neck dissection and radical tonsillectomy. Twenty-six patients were HPV+, 28 were nonsmokers or long-term former smokers, and 28 were T1/T2. Fourteen patients required postoperative chemoradiotherapy (CRT). Median follow-up time was 4.1 years.Results: A complete response to induction chemotherapy was achieved in 45% (17) of patients. In total, 76% (29/38) of patients were successfully treated: 53% (20/38) with chemotherapy and surgery alone, and 24% (9/38) required postoperative CRT. Almost 90% (23/26) of HPV+ and half (6/12) of HPV− patients are no evidence of disease (NED). HPV status is a significant prognostic factor (P = .02). Only 38% (5/13) of current smokers were NED compared to 96% (24/25) of nonsmokers (P = .0002). All HPV+ nonsmokers (20/20) were NED at last follow-up.Conclusions: In this study, the primary driver of prognosis was smoking status. HPV status and T stage were also important. The prognosis for HPV+ nonsmokers is extremely good; most likely regardless of treatment. Treatment failures have a poor chance of salvage, irrespective of treatment type. With the major exception of HPV− smokers, induction chemotherapy followed by surgery with selective CRT is a viable treatment option for tonsil cancer.

show abstract

Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck

Cited by 12 publications

References 37 publications

Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma

Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma

Multiple Administrations of Viral Nanoparticles Alter in Vivo Behavior—Insights from Intravital Microscopy

Presurgical induction chemotherapy for squamous cell carcinoma of the tonsil

Contact Info

Product

Resources

About